At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 26, 2026 at 16:05 ET
Zentalis Pharmaceuticals reported its 2025 financial results, highlighting a significant reduction in R&D and G&A expenses, with $245.9 million in cash providing a runway into late 2027. The company remains on track for key 2026 milestones, including dose confirmation in 1H 2026 and a topline readout from the DENALI Part 2 trial by year-end, which could support accelerated FDA approval of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer.
- Cash, cash equivalents, and marketable securities totaled $245.9 million as of December 31, 2025, sufficient to fund operations into late 2027.
- R&D expenses decreased to $107.3 million in 2025 from $167.8 million in 2024, driven by lower clinical, lab, manufacturing, and personnel costs.
- G&A expenses dropped to $37.7 million in 2025 from $87.1 million in 2024, largely due to a $47.1 million reduction in personnel expenses, including $40.8 million in non-cash stock-based compensation.
- No revenue was recorded in 2025, compared to $67.4 million in licensing revenue in 2024 from a prior collaboration.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access